Literature DB >> 30142007

Adherence and resource use among psoriasis patients treated with biologics.

Joseph S Aleshaki1, Leah A Cardwell1, Mikél E Muse1, Steven R Feldman1,2,3.   

Abstract

INTRODUCTION: The emergence of immune-modulating drugs such as biologics has altered the treatment landscape for psoriasis. However, their use presents high financial costs to patients and healthcare systems. Patient demographic and socioeconomic status may influence adherence to biologic medications and usage of healthcare resources. AREAS COVERED: We performed a systematic literature review to summarize the available evidence pertaining to biologic medication adherence and resource use. PubMed was searched using the terms 'psoriasis and adherence' and 'psoriasis biologics resource use.' EXPERT COMMENTARY: Psoriasis patients utilize many healthcare resources. Adherence rates are typically higher for biologics than for other psoriasis treatment categories. However, adherence rates are still suboptimal.

Entities:  

Keywords:  Adherence; biologics; drug cost; healthcare resource use; psoriasis

Mesh:

Substances:

Year:  2018        PMID: 30142007     DOI: 10.1080/14737167.2018.1512408

Source DB:  PubMed          Journal:  Expert Rev Pharmacoecon Outcomes Res        ISSN: 1473-7167            Impact factor:   2.217


  5 in total

1.  Relationship between serum trough levels and efficacy of brodalumab from a post hoc exploratory analysis of a Japanese study in patients with plaque psoriasis.

Authors:  Yukie Yamaguchi; Yasumasa Kanai; Hiroki Kitabayashi; Hiroki Okada; Hidemi Nakagawa
Journal:  J Dermatol       Date:  2020-11-08       Impact factor: 4.005

2.  Adherence to systemic therapy in patients with psoriasis during the COVID-19 pandemic: A multicenter study.

Authors:  Ilteris Oguz Topal; Asude Kara Polat; İlkin Zindancı; İlknur Kıvanç Altunay; Tuğba Özkök Akbulut; Eylem Emel Arıkan; Filiz Topaloğlu Demir; Onur Sivaz; Ayşe Serap Karadağ
Journal:  J Cosmet Dermatol       Date:  2021-11-18       Impact factor: 2.189

3.  Expert Perspectives on Key Parameters that Impact Interpretation of Randomized Clinical Trials in Moderate-to-Severe Atopic Dermatitis.

Authors:  Jonathan I Silverberg; Eric L Simpson; April W Armstrong; Marjolein S de Bruin-Weller; Alan D Irvine; Kristian Reich
Journal:  Am J Clin Dermatol       Date:  2021-10-26       Impact factor: 7.403

Review 4.  Adherence and Persistence to Biological Drugs for Psoriasis: Systematic Review with Meta-Analysis.

Authors:  Eugenia Piragine; Davide Petri; Alma Martelli; Agata Janowska; Valentina Dini; Marco Romanelli; Vincenzo Calderone; Ersilia Lucenteforte
Journal:  J Clin Med       Date:  2022-03-09       Impact factor: 4.241

5.  Risk of major adverse cardiovascular events in patients initiating biologics/apremilast for psoriatic arthritis: a nationwide cohort study.

Authors:  Laura Pina Vegas; Philippe Le Corvoisier; Laetitia Penso; Muriel Paul; Emilie Sbidian; Pascal Claudepierre
Journal:  Rheumatology (Oxford)       Date:  2022-04-11       Impact factor: 7.046

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.